surmount-1 tirzepatide trial obesity without diabetes

surmount-1 tirzepatide trial obesity without diabetes surmount once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically Reduces Weight – Tirzepatide once weekly for the

Name: surmount-1 tirzepatide trial obesity without diabetes surmount once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically Reduces Weight – Tirzepatide once weekly for the
Brand: actil.am
SKU: 58951204965
Price: 26.18 USD
Availability: InStock
Rating: 4.4329 (8 reviews)

SKU: 58951204965

4.4

USD26.18 USD73.18

Pay in 4 interest-free payments of $6.54 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 27 - Sep 1

Description

Be part of groundbreaking Long COVID research from Scripps Research We endeavor to conduct a portfolio of Long COVID clinical trials within our Long COVID Treatment Trial (LoCITT) program, operated by Scripps Research in partnership with CareEvolution and funded by the Schmidt Initiative for Long COVID (SILC)